MX2018008095A - Compuestos heterociclicos triciclicos condensados como inhibidores de integrasa del vih. - Google Patents
Compuestos heterociclicos triciclicos condensados como inhibidores de integrasa del vih.Info
- Publication number
- MX2018008095A MX2018008095A MX2018008095A MX2018008095A MX2018008095A MX 2018008095 A MX2018008095 A MX 2018008095A MX 2018008095 A MX2018008095 A MX 2018008095A MX 2018008095 A MX2018008095 A MX 2018008095A MX 2018008095 A MX2018008095 A MX 2018008095A
- Authority
- MX
- Mexico
- Prior art keywords
- tricyclic heterocyclic
- fused tricyclic
- heterocyclic compounds
- hiv integrase
- integrase inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/16—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2015/100106 WO2017113288A1 (en) | 2015-12-31 | 2015-12-31 | Fused tricyclic heterocyclic compounds as hiv integrase inhibitors |
| PCT/US2016/068173 WO2017116928A1 (en) | 2015-12-31 | 2016-12-22 | Fused tricyclic heterocyclic compounds as hiv integrase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018008095A true MX2018008095A (es) | 2018-08-23 |
Family
ID=57799839
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018008095A MX2018008095A (es) | 2015-12-31 | 2016-12-22 | Compuestos heterociclicos triciclicos condensados como inhibidores de integrasa del vih. |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US20170190701A1 (enExample) |
| EP (1) | EP3397639B1 (enExample) |
| JP (1) | JP2019500387A (enExample) |
| KR (1) | KR20180095833A (enExample) |
| CN (1) | CN108473494A (enExample) |
| AR (1) | AR107170A1 (enExample) |
| AU (1) | AU2016381072B2 (enExample) |
| BR (1) | BR112018013251A2 (enExample) |
| CA (1) | CA3008018A1 (enExample) |
| JO (1) | JO3811B1 (enExample) |
| MA (1) | MA43528A (enExample) |
| MX (1) | MX2018008095A (enExample) |
| RU (1) | RU2740187C2 (enExample) |
| TW (1) | TW201726683A (enExample) |
| WO (2) | WO2017113288A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10081647B2 (en) * | 2015-03-26 | 2018-09-25 | Merck Sharp & Dohme Corp. | Phosphate substituted quinolizine derivatives useful as HIV integrase inhibitors |
| JOP20190130A1 (ar) | 2016-12-02 | 2019-06-02 | Merck Sharp & Dohme | مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv) |
| WO2018102634A1 (en) | 2016-12-02 | 2018-06-07 | Merck Sharp & Dohme Corp. | Tricyclic heterocycle compounds useful as hiv integrase inhibitors |
| WO2019209667A1 (en) * | 2018-04-27 | 2019-10-31 | Merck Sharp & Dohme Corp. | Tricyclic heterocycle compounds useful as hiv integrase inhibitors |
| EP3805221A4 (en) | 2018-05-31 | 2022-01-05 | Shionogi & Co., Ltd | POLYCYCLIC PYRIDONE DERIVATIVE |
| CR20230571A (es) | 2018-05-31 | 2024-01-22 | Shionogi & Co | DERIVADO POLICÍCLICO DE CARBAMOILPIRIDONA (divisional 2020-0644) |
| US11884683B2 (en) | 2018-06-05 | 2024-01-30 | Merck Sharp & Dohme Llc | Tricyclic heterocycle compounds useful as HIV integrase inhibitors |
| EP4751717A3 (en) * | 2018-10-22 | 2026-08-05 | Board of Regents of the University of Nebraska | Antiviral prodrugs and nanoformulations thereof |
| KR20240151256A (ko) | 2019-03-22 | 2024-10-17 | 길리애드 사이언시즈, 인코포레이티드 | 가교된 트리시클릭 카르바모일피리돈 화합물 및 그의 제약 용도 |
| US20200398978A1 (en) | 2019-06-20 | 2020-12-24 | Bell Helicopter Textron Inc. | Low-drag rotor blade extension |
| US12564595B2 (en) | 2019-11-28 | 2026-03-03 | Shionogi & Co., Ltd. | Prophylactic and therapeutic pharmaceutical agent for HIV infectious diseases characterized by comprising combination of integrase inhibitor and anti-HIV agent |
| WO2021107065A1 (ja) | 2019-11-28 | 2021-06-03 | 塩野義製薬株式会社 | 多環性ピリドピラジン誘導体 |
| EP4110783A1 (en) * | 2020-02-24 | 2023-01-04 | Gilead Sciences, Inc. | Tetracyclic compounds for treating hiv infection |
| CN116390924B (zh) | 2020-09-30 | 2025-11-07 | 吉利德科学公司 | 桥连三环氨基甲酰基吡啶酮化合物及其用途 |
| CR20260070A (es) | 2021-01-19 | 2026-04-24 | Gilead Sciences Inc | COMPUESTOS DE PIRIDOTRIAZINA SUSTITUIDOS Y USOS DE ESTOS (Divisional 2023-0315) |
| US11958864B2 (en) * | 2021-02-16 | 2024-04-16 | Merck Sharp & Dohme Llc | Tetracyclic heterocycle compounds useful as HIV integrase inhibitors |
| TWI856796B (zh) | 2022-04-06 | 2024-09-21 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE530520T1 (de) | 2001-08-10 | 2011-11-15 | Shionogi & Co | Antivirales mittel |
| DE122009000048I1 (de) | 2001-10-26 | 2010-04-08 | Angeletti P Ist Richerche Bio | N-substituierte hydroxypyrimidinoncarboxamid-hemmer der hiv-integrase |
| CA2463975A1 (en) | 2001-10-26 | 2003-05-01 | Maria Emilia Di Francesco | Dihydroxypyrimidine carboxamide inhibitors of hiv integrase |
| EP1467970B1 (en) | 2002-01-17 | 2007-08-22 | Merck & Co., Inc. | Hydroxynaphthyridinone carboxamides useful as hiv integrase inhibitors |
| WO2004058756A1 (en) | 2002-12-27 | 2004-07-15 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Tetrahydro-4h-pyrido[1,2-a]pyrimidines and related compounds useful as hiv integrase inhibitors |
| WO2004062613A2 (en) | 2003-01-13 | 2004-07-29 | Bristol-Myers Squibb Company | Hiv integrase inhibitors |
| US7037908B2 (en) | 2003-04-24 | 2006-05-02 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| TW200510425A (en) | 2003-08-13 | 2005-03-16 | Japan Tobacco Inc | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor |
| AR046938A1 (es) | 2003-12-12 | 2006-01-04 | Merck & Co Inc | Procedimiento para preparar hexahidropirimido[1,2-a]azepin-2-carboxilatos y compuetos similares |
| TW200526635A (en) | 2003-12-22 | 2005-08-16 | Shionogi & Co | Hydroxypyrimidinone derivative having HIV integrase inhibitory activity |
| AU2005221864A1 (en) * | 2004-03-09 | 2005-09-22 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | HIV integrase inhibitors |
| US7273859B2 (en) | 2004-05-12 | 2007-09-25 | Bristol-Myers Squibb Company | HIV integrase inhibitors: cyclic pyrimidinone compounds |
| US7115601B2 (en) | 2004-05-18 | 2006-10-03 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| US7192948B2 (en) | 2004-05-28 | 2007-03-20 | Bristol-Myers Squibb Company | Bicyclic heterocycles as HIV integrase inhibitors |
| US7176196B2 (en) | 2004-05-28 | 2007-02-13 | Bristol-Myers Squibb Company | Bicyclic heterocycles as HIV integrase inhibitors |
| US7173022B2 (en) | 2004-05-28 | 2007-02-06 | Bristol-Myers Squibb Company | Bicyclic heterocycles as HIV integrase inhibitors |
| US7157447B2 (en) | 2004-05-28 | 2007-01-02 | Bristol-Myers Squibb Company | Bicyclic heterocycles as HIV integrase inhibitors |
| WO2006103399A1 (en) | 2005-03-31 | 2006-10-05 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Hiv integrase inhibitors |
| US7494984B2 (en) | 2005-08-31 | 2009-02-24 | Bristol-Myers Squibb Company | Substituted imidazo[1,2-a]pyrimidines as HIV viral DNA integrase inhibitors |
| CN101346376A (zh) * | 2005-10-27 | 2009-01-14 | 盐野义制药株式会社 | 具有hiv整合酶抑制活性的多环性氨基甲酰基吡啶酮衍生物 |
| WO2007059125A2 (en) | 2005-11-15 | 2007-05-24 | Bristol-Myers Squibb Company | Hiv integrase inhibitors |
| US7902182B2 (en) | 2005-11-16 | 2011-03-08 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| US8039458B2 (en) | 2005-11-17 | 2011-10-18 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| WO2007143446A1 (en) | 2006-05-30 | 2007-12-13 | Bristol-Myers Squibb Company | Spiro-condensed heterotricyclic compounds as hiv integrase inhibitors |
| US7893055B2 (en) | 2006-06-28 | 2011-02-22 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| JP4833385B1 (ja) * | 2008-10-07 | 2011-12-07 | アクテリオン ファーマシューティカルズ リミテッド | 三環式オキサゾリジノン抗生物質化合物 |
| WO2011045330A1 (en) | 2009-10-13 | 2011-04-21 | Tibotec Pharmaceuticals | Macrocyclic integrase inhibitors |
| WO2011121105A1 (en) | 2010-04-02 | 2011-10-06 | Tibotec Pharmaceuticals | Macrocyclic integrase inhibitors |
| US9493479B2 (en) * | 2013-04-16 | 2016-11-15 | Merck Sharp & Dohme Corp. | Substituted pyrido[1,2-a]pyrazines as HIV integrase inhibitors |
| SI2997033T1 (en) * | 2013-05-17 | 2018-04-30 | Merck Sharp & Dohme Corp. | FUZYCLE TRICYCLE HETEROCYCLIC COMPOUNDS AS HIV INTEGRATED INHIBITORS |
-
2015
- 2015-12-31 WO PCT/CN2015/100106 patent/WO2017113288A1/en not_active Ceased
-
2016
- 2016-12-22 JP JP2018534101A patent/JP2019500387A/ja active Pending
- 2016-12-22 RU RU2018127728A patent/RU2740187C2/ru active
- 2016-12-22 AR ARP160103990A patent/AR107170A1/es unknown
- 2016-12-22 CN CN201680073126.9A patent/CN108473494A/zh active Pending
- 2016-12-22 KR KR1020187018217A patent/KR20180095833A/ko not_active Withdrawn
- 2016-12-22 WO PCT/US2016/068173 patent/WO2017116928A1/en not_active Ceased
- 2016-12-22 AU AU2016381072A patent/AU2016381072B2/en not_active Ceased
- 2016-12-22 TW TW105142826A patent/TW201726683A/zh unknown
- 2016-12-22 MX MX2018008095A patent/MX2018008095A/es unknown
- 2016-12-22 CA CA3008018A patent/CA3008018A1/en not_active Abandoned
- 2016-12-22 EP EP16826561.9A patent/EP3397639B1/en active Active
- 2016-12-22 JO JOP/2016/0271A patent/JO3811B1/ar active
- 2016-12-22 BR BR112018013251A patent/BR112018013251A2/pt not_active Application Discontinuation
- 2016-12-22 MA MA043528A patent/MA43528A/fr unknown
- 2016-12-22 US US15/387,732 patent/US20170190701A1/en not_active Abandoned
-
2017
- 2017-12-13 US US15/840,017 patent/US20180099967A1/en not_active Abandoned
-
2019
- 2019-06-27 US US16/454,857 patent/US20190322666A1/en not_active Abandoned
-
2020
- 2020-10-27 US US17/081,094 patent/US20210040096A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| RU2018127728A (ru) | 2020-02-03 |
| RU2018127728A3 (enExample) | 2020-02-14 |
| AU2016381072B2 (en) | 2020-11-26 |
| AU2016381072A1 (en) | 2018-05-31 |
| AR107170A1 (es) | 2018-03-28 |
| US20170190701A1 (en) | 2017-07-06 |
| MA43528A (fr) | 2018-11-07 |
| US20180099967A1 (en) | 2018-04-12 |
| BR112018013251A2 (pt) | 2018-12-04 |
| US20210040096A1 (en) | 2021-02-11 |
| US20190322666A1 (en) | 2019-10-24 |
| EP3397639B1 (en) | 2022-02-23 |
| WO2017113288A1 (en) | 2017-07-06 |
| KR20180095833A (ko) | 2018-08-28 |
| WO2017116928A1 (en) | 2017-07-06 |
| CA3008018A1 (en) | 2017-07-06 |
| TW201726683A (zh) | 2017-08-01 |
| JO3811B1 (ar) | 2021-01-31 |
| EP3397639A1 (en) | 2018-11-07 |
| JP2019500387A (ja) | 2019-01-10 |
| CN108473494A (zh) | 2018-08-31 |
| RU2740187C2 (ru) | 2021-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019501198A1 (en) | Tetracyclic heterocycle compounds useful as hiv integrase inhibitors | |
| PH12016500553A1 (en) | Substituted quinolizine derivatives useful as hiv integrase inhibitors | |
| MX2022012317A (es) | Oxisteroles y metodos de uso de los mismos. | |
| PH12018500061A1 (en) | Oxysterols and methods of use thereof | |
| PH12018500065A1 (en) | Oxysterols and methods of use thereof | |
| MX2016014728A (es) | Dihidroquinolizidinonas novedosas para el tratamiento y profilaxis de la infeccion con virus de la hepatitis b. | |
| PH12015502443A1 (en) | 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection | |
| BR112018013251A2 (pt) | compostos heterocílicos tricíclicos fundidos como inibidores da hiv integrase | |
| MX2021014531A (es) | Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos. | |
| DK2997033T3 (da) | Kondenserede tricykliske heterocykliske forbindelser som hiv- integrasehæmmere | |
| NZ703064A (en) | Inhibitors of hepatitis c virus | |
| PH12019500432B1 (en) | 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection | |
| EA201791304A1 (ru) | Производные изохинолина для лечения вич | |
| MD20160136A2 (ro) | Compuşi dihidroizochinolinonici substituiţi | |
| MX2019006449A (es) | Compuestos heterociclicos triciclicos utiles como inhibidores de la integrasa del virus de inmunodeficiencia humana (vih). | |
| PH12017502009A1 (en) | Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection | |
| EA201650003A1 (ru) | Соединённые циклоалкилом дигетероциклические производные | |
| EA202191885A3 (ru) | Бициклические гетероциклические производные в качестве ингибиторов irak4 |